Background: miRNA profiling across different stages of laryngeal carcinogenesis explores dysregulated molecules relevant to engaged gene pathways and identifies markers for differential diagnosis and prognosis in early mucosal lesions of the larynx. Methods: Tissue samples were prospectively collected from 28 patients with hypertrophic vocal fold lesions: no dysplasia (ND), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and invasive cancer (IC), as well as from 3 patients with vocal fold polyps. miRNA profiling of the samples was performed using microfluidic cards—TaqMan^® Human MicroRNA Array A. A comparative analysis of ΔCt (dCt) miRNA expression levels was conducted between groups. Results: hsa-miR-216a-5p and hsa-miR-488-3p were selectively expressed in control tissues, while hsa-miR-105-5p and hsa-miR-516a-5p were exclusively detected in HGD and IC samples. Significant differences in miRNA expression were identified across 4, 16, 17, and 38 miRNA types between control and ND, LGD, HGD, and IC groups, respectively. hsa-miR-185-5p and hsa-miR-21-5p showed significantly altered expression between ND and LGD, HGD, and IC (p = 0.026, 0.001, 0.002; and p = 0.021, 0.002, 0.001, respectively). Twenty-five miRNAs were differentially expressed between LGD and both HGD and IC, while eleven miRNAs distinguished HGD from IC. Notably, hsa-miR-503-5p expression decreased progressively with increasing histological severity. Conclusions: Distinct miRNA expression profiles are associated with progressive stages of laryngeal mucosal lesions. Specific miRNAs may serve as valuable biomarkers for early detection, risk stratification, and prognosis in vocal fold carcinogenesis.

Human parechoviruses, officially known as Parechovirus A (PeV-A), are more frequently reported as a significant cause of serious infections in newborns and young infants. We aimed to describe the clinical features and neurological outcomes of PeV-A encephalitis cases identified in Warsaw. Infants with suspected encephalitis were retrospectively identified in three hospitals in the summer of 2022. Cases of confirmed PeV-A infection had their comprehensive demographic, clinical, laboratory, imaging, and outcome data reviewed. The psychomotor development of the children up to the age of 2 years was assessed by using the standardized tools. We identified 18 cases of confirmed encephalitis with a PeV-A infection. Their median age was 16 days. Fourteen cases were included in the analysis, while one patient dropped out after the first visit. Most were boys (9/14), and one patient was born preterm. Three patients had white matter alterations on brain MRI at discharge. No significant neurologic sequelae were observed after acute illness. At the 24-month follow-up, based on the Bayley Scales of Infant and Toddler Development (BSID-IV) and the Brunet–Lézine Scale, the children showed no neurodevelopmental sequelae. Brain MRIs were obtained in all of the participants up to 12 months of age and revealed no significant lesions. Neurodevelopmental complications are not frequent in children after PeV-A encephalitis at 24 months of age. Continued follow-up in larger cohorts is needed to explore the predictors of long-term morbidity.